BioSpace News Archive

In many ways, licensing deals have become part of the life’s blood of the biopharma industry. According to a new report released by the global consulting firm Charles River Associates (CRA), approximately 75 percent of all new biologics and small molecules launched in the United States were not discovered by the company or entity that commercialized the product.

Concern Tecmash (part of Rostec) has presented the first sample of modernized Angel automated diagnostic and therapeutic system for human life support at the BIOTECHMED forum.

Heralds a new strategy for fighting cancer: Drugs that target two genes at a time

Imugene Limited today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.

Partnership combines Intellegens’ proprietary AI technology withOptibrium’s expertise in predictive modelling and compound design

Sector Generates Significant Year-to-Date Leasing Volume – with More to Come

FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints

IRBM signs collaboration agreement with Merck & Co., Inc, Kenilworth, NJ, USA to advance peptide therapeutics

NHS patients to benefit from Europe’s first full access deal on breakthrough CAR-T therapy.

Adaptimmune Therapeutics plc today announced that it has entered into a definitive agreement with Matrix Capital Management Company